COVID-19 Pandemic Burden in Severe Mental Disease Patients

COVID Clinical Trial

— PsyCOVID  

Official title:

A Study of Perceived Distress and Psychological Burden in Patients Suffering From Severe Mental Diseases During the COVID-19 Pandemic in Italy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04357769
• Other study ID #: 152/20
• Status: Completed
• Start date: April 10, 2020
• Est. completion date: April 25, 2020

Study information

• Verified date: February 2021
• Source: Federico II University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Despite being originated in Wuhan, in the China mainland region of the Hubei, Italy has been the hardest-hit country in the world by the COVID-19 pandemic during the month of March.

Due to the uncontrollable spread of the contagion, the Italian Government has been forced to impose a series of restrictions and social distancing measures, culminating in the extension of lockdown to the entire Italian territory on March 8th.

During this period, the general population has been overwhelmed by feelings of worry, anxiety, and discomfort. The discomfort is reinforced by the lengthening of the lockdown, to the point that it may be considered as a mass model of chronic or subchronic mild stress.

The predictable effects of this stress on mental health have already been claimed, Post-traumatic symptoms were found in 7% among 285 Wuhan and surrounding cities' residents during the COVID-19 outbreak. A recent survey in the Italian general population reported similar outcomes.

In this context, the psychic conditions of the most fragile ones, i.e. those already affected by a severe mental disorder, represent a major concern. Having a history of psychiatric illness is regarded as one of the most relevant predictors of a negative psychological impact of quarantine. Patients with severe mental disorders may be among the hardest hit subjects, as they may be more vulnerable by the COVID-19 outbreak for a series of clinical and psychological factors. In the Italian context, the vulnerability of these patients may be increased by the lockdown of mental health services as a consequence of mass quarantine and optimization of health resources toward action to contrast COVID-19-related sanitary emergencies.

Despite several reports investigated the psychological effects of COVID-19 pandemic on health-care workers, COVID-19 affected people, or the general population, at the moment, no study has investigated the effects of the distress caused by fear of contagion and mass quarantine on severe mental disorder patients. The present study aimed at providing a first evaluation of anxiety, depressive, stress-related symptoms in these patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 400
• Est. completion date: April 25, 2020
• Est. primary completion date: April 20, 2020
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• DSM-5 Diagnosis of Schizophrenia or Psychosis Spectrum; Bipolar Disorder; REcurrent Major Depressive Disorder

• Linguistic and cognitive ability to complete the rating scales

• Written informed consent

• Psychopathological compensation at last clinical evaluation on January-February 2020

Exclusion Criteria:

• SARS-CoV-2 positive, suspected positive, or in recent close contact with positive ones

• Not under strict quarantine, due to work reasons or to any other reason allowing to overcome quarantine

• Current or recent hospitalization (i.e. on March-April), for any reason

• Intellectual disability

• Psychiatric disturbances secondary to general medical conditions or substances

• Serious medical conditions with infaust prognosis or severely affecting the quality of life

• Living in Northern Italy

Adjunctive Exclusion Criteria for the General Population and Caregivers:

• Psychiatric Disorder, of any type

Adjunctive Exclusion Criteria for the General Population:

• First degree relative or caregiver of a psychiatric patient

Related Conditions & MeSH terms

• COVID
• Mental Disorders
• Psychological Distress
• Severe Mental Disorder

Intervention

Other:
• PSS (Perceived Stress Scale)
Self-administered scale for the evaluation of the stress perceived by the subject in the last weeks
• GAD-7 (7-item Generalized Anxiety Disorder)
Self-administered scale for the evaluation of anxiety symptoms in the last weeks
• PHQ-9 (9-item Patient Health Questionnaire)
Self-administered scale for the evaluation of depressive symptoms in the last weeks
• SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales
Self-administered scale for the evaluation of sub-threshold psychotic symptoms in the last weeks
• Zaritt Burden Interview
Self-administered scale for the evaluation of severe mental disorder patients' caregiver burden

Locations

Country	Name	City	State
Italy	University of Naples "Federico II"	Napoli

Sponsors (1)

Lead Sponsor	Collaborator
Federico II University

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Perceived Stress Scale (PSS) outcome	Significant differences among groups in the mean Perceived Stress Scale (PSS) score, which measures the stress severity perceived by the subjects in the last month. The scale is constituted by 10 items that are self-rated by the subject on a 0-4 Likert scale. The scale minimum total score is 0, the maximum is 40. Higher total scores indicate a worse outcome	10 days
Secondary	Generalized Anxiety Disorder (GAD-7) scale outcome	Significant differences among groups in the mean Generalized Anxiety Disorder (GAD-7) scale score, which measures anxiety symptoms' severity in the last two weeks. The scale is constituted by 7 items that are self-rated by the subject on a 0-3 Likert scale. The scale minimum total score is 0, the maximum is 21. Higher total scores indicate a worse outcome	10 days
Secondary	Patient Health Questionnaire (PHQ-9) scale outcome	Significant differences among groups in the mean Patient Health Questionnaire (PHQ-9) scale score, which measures depressive symptoms' severity in the last two weeks. The scale is constituted by 9 items that are self-rated by the subject on a 0-3 Likert scale. The scale minimum total score is 0, the maximum is 21. Higher total scores indicate a worse outcome	10 days
Secondary	Specific Psychotic Experiences Questionnaire (SPEQ) - Paranoia subscale outcome	Significant differences among groups in the mean Specific Psychotic Experiences Questionnaire (SPEQ) - Paranoia subscale score. The SPEQ scale is designed for the assessment of current sub-threshold psychotic symptoms in multiple domains. The Paranoia subscale measures persecutory/reference ideas and is constituted by 15 items that are self-rated by the subject on a 0-5 Likert scale. The subscale minimum total score is 0, the maximum is 75. Higher total scores indicate a worse outcome	10 days
Secondary	Specific Psychotic Experiences Questionnaire (SPEQ) - Grandiosity subscale outcome	Significant differences among groups in the mean Specific Psychotic Experiences Questionnaire (SPEQ) - Grandiosity subscale score. The Grandiosity subscale measures grandiosity/megalomaniac ideas and is constituted by 8 items that are self-rated by the subject on a 0-3 Likert scale. The subscale minimum total score is 0, the maximum is 24. Higher total scores indicate a worse outcome	10 days
Secondary	Caregiver Burden	Significant correlations between mean Zarit Burden Interview (ZBI) and mean scores on the Perceived Stress Scale (PSS). The ZBI is designed for the assessment of caregiver burden. The scale is constituted by 22 items that are self-rated by the subject on a 0-4 Likert scale. The scale minimum total score is 0, the maximum is 88. Higher total scores indicate a worse outcome	10 days